Ron DePinho: A Negative Trial Does Not Repudiate Inflammation as a Cardiovascular Target
Ron DePinho, Professor at Department of Cancer Biology, Harry Graves Burkhart III Distinguished University Chair Cancer Biology at MD Anderson Cancer Center, shared a post on LinkedIn:
“Disappointing for this program, but definitely not a repudiation of inflammation as a cardiovascular target.
The key question will be whether the trial tested the right inflammatory biology, in the right patients, at the right stage of disease.
Cardiovascular inflammation is not a single pathway or biomarker; it is a dynamic network shaped by residual lipid risk, obesity and metabolic dysfunction, clonal hematopoiesis, immune aging, and tissue injury.
The field should learn as much from a negative trial as from a positive one. We need better mechanistic patient stratification, pharmacodynamic biomarkers that demonstrate pathway engagement in the relevant tissue, and combination strategies matched to the biology of residual risk.
The inflammatory hypothesis remains compelling in my view … it is likely that its clinical translation clearly requires greater precision.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 16:48Abdul Rahman: Reticulocyte Count and Bone Marrow Activity
-
Oct 16, 2026, 16:44DOAC Adherence in Stroke Patients With Atrial Fibrillation – International Journal of Stroke
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs